Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SABS
SELLSAB Biotherapeutics, Inc. · Healthcare · United States · $268M · Avg Vol: $3M/d
COMPANY DESCRIPTION
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies based on its proprietary DiversitAb platform, which utilizes transchromosomic cattle to produce fully human polyclonal antibodies. This unique technology provides a distinct competitive moat, enabling the generation of high-affinity antibodies with broad therapeutic potential across infectious diseases, oncology, and autoimmune disorders. As an early-stage biotech, SAB Biotherapeutics represents a high-risk, high-reward investment focused on disruptive antibody-based treatments.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 62.5K | — |
| EPS | -6.30 | -0.28 | -0.92 | -0.45 | 0.22 | — | -0.58 | — | — |
| Shares | — | 76.5M | 76.5M | 76.5M | 47.6M | -37.7% | — | — | — |
| Debt | — | 5.9M | 5.9M | 4.7M | 6.0M | 0.1% | 6.2M | — | — |
| Equity | — | 31.1M | 57.3M | 26.0M | 151.5M | 69.6% | — | — | — |
| Op CF | — | -23.5M | -25.1M | -34.3M | -44.8M | — | -51.2M | — | — |
| Inv CF | — | -2.1M | -0.2M | -12.0M | -121.7M | — | — | — | — |
| Fin CF | — | 1.1M | 66.8M | -1.2M | 168.3M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SABS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc.(you) | $268M | 27 | SELL |
| FATE | Fate Therapeutics, Inc. | $281M | 26 | SELL |
| MGNX | MacroGenics, Inc. | $235M | 26 | SELL |
| VNDA | Vanda Pharmaceuticals Inc. | $312M | 26 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 28 | SELL |
| ALXO | ALX Oncology Holdings Inc. | $273M | 31 | SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 24 | SELL |
| ELDN | Eledon Pharmaceuticals, Inc. | $276M | 33 | SELL |
| OABI | OmniAb, Inc. | $294M | 32 | SELL |
| IMRX | Immuneering Corporation | $279M | 21 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%